DISARM – „Disarming the silent threat of ovarian cancer“
- Project No.: 101214318
- Project acronym: DISARM
- Principal investigator (LSMU): Prof. Daiva Vaitkienė and Prof. Rasa Ugenskienė
- Project coordinator: EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI
YPOLOGISTON (ICCS)
- Total project value: 11 999 086,75 Eur
- Part of the project value allocated to the LSMU: 802 396,25 Eur
- Project duration: from 2025-09-01 to 2029-08-31
- Funding programme: Horizon Europe
- Project website: https://disarm-project.eu/
DISARM is a 48-month European research and innovation project funded by the European Union under the Horizon Europe Programme, bringing together 28 partners from 12 countries. The project aims to improve ovarian cancer risk assessment and early detection through innovative diagnostic technologies, personalised prevention strategies, and digital health solutions.
The project focuses on evaluating the CanRisk risk assessment tool, based on the BOADICEA model, which integrates genetic, lifestyle, demographic, and hormonal factors alongside polygenic risk scores. Its feasibility, acceptability, and cost-effectiveness will be assessed in Portugal, Lithuania, the Czech Republic, and Greece.
In parallel, three minimally invasive liquid biopsy approaches will be evaluated in more than 2,000 patients across five European countries: the United Kingdom, Portugal, Lithuania, the Czech Republic, and Greece. These include OVA-GLY (glycoprotein biomarkers in blood serum), OVA-VOC (volatile organic compound patterns in plasma), and OVA-miRNA (circulating microRNA signatures).
The clinical research is complemented by innovative digital solutions, including OVA-ONLINE for genetic counselling and patient support, OVA-MULTIMODAL for integrating biomarker data, and OVA-VIEW, a policy dashboard supporting evidence-based healthcare decision-making.
The Lithuanian University of Health Sciences (LSMU) contributes to the development and evaluation of hereditary ovarian cancer risk assessment and early detection approaches, supports clinical research activities, and promotes the integration of innovative diagnostic tools and personalised prevention strategies into the Lithuanian healthcare system.
The expected outcome of the project: The DISARM project aims to improve ovarian cancer prevention and early detection by developing and validating innovative, personalised, accessible, and cost-effective risk assessment and diagnostic approaches. Through the clinical evaluation of the CanRisk tool and minimally invasive liquid biopsy technologies, the project will generate scientific evidence on their feasibility, acceptability, and cost-effectiveness in European healthcare settings. By actively involving patients, healthcare professionals, patient advocacy organisations, researchers, and policymakers, DISARM seeks to support the development of patient-centred early detection programmes and facilitate their wider implementation. The project will also provide evidence-based recommendations and a practical roadmap for integrating these innovations into national healthcare systems, addressing financial, regulatory, ethical, and organisational challenges. In Lithuania, the results are expected to contribute to the introduction of innovative ovarian cancer risk assessment and early detection methods into clinical practice, strengthening personalised cancer prevention, improving healthcare services, and ultimately enhancing patient outcomes and quality of life.
PROJECT PARTNERS
- INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL EPE (IPOL), Portugal;
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (ICL), SW7 2AZ, United Kingdom;
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON (UOA), Greece;
- UNIVERZITA KARLOVA (CU), Czechia;
- LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS (LSMU), Lithuania;
- NATIONAL CENTER FOR SCIENTIFIC RESEARCH „DEMOKRITOS” (Demokritos), Greece;
- KYPRIAKO IDRYMA EREVNON GIA TI MYIKI DISTROFIA (CING), Cyprus;
- VOC DIAGNOSTICS AB (VOC-D), Sweden;
- EREVNITIKO IDRIMA P.L. (UNRF), Cyprus;
- THE UNIVERSITY OF BIRMINGHAM (UoB), United Kingdom;
- TIMELEX (TLX), Belgium;
- KATHOLIEKE UNIVERSITEIT LEUVEN (KU Leuven), Belgium;
- ASSOCIACAO EVITA – CANCRO HEREDITARIO (EVITA), Portugal;
- ELLINIKI OMOSPONDIA KARKINOU ELL OK (ELLOK), Greece;
- WORLD OVARIAN CANCER COALITION (The Coalition), Canada;
- EXUS SOFTWARE MONOPROSOPI ETAIRIA PERIORISMENIS EVTHINIS (EXUS), Greece;
- CARE ACROSS LTD (CARE), United Kingdom;
- ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH), Greece;
- AINIGMA TECHNOLOGIES (AIN), Belgium;
- 1ST YGEIONOMIKI PERIFEREIA DYPE ATTIKIS (1ST YPE), Greece;
- LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (SAM LT), Lithuania;
- UNIVERSIDAD DE LA RIOJA (UNIRIOJA), Spain;
- EY ADVISORY SPA (EY), Italy;
- CARR COMMUNICATIONS LIMITED (CARR), Ireland;
- PHAZE KLINIKI EREVNA & FARMAKEFTIKES SYMVOULES ANONYMI ETAIREIA (PHAZE), Greece;
- VSEOBECNA FAKULTNI NEMOCNICE V PRAZE (GUHP), Czechia;
- FAKULTNI NEMOCNICE BULOVKA (BUH), Czechia